Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sildenafil - Pfizer

Next Previous
Drug Profile

Sildenafil - Pfizer

Alternative Names: Revatio; Revatio IV; Sildenafil citrate; Sildenafil Citrate ODF - Pfizer; Sildenafil citrate orally-disintegrating film - Pfizer; UK 92480; Viagra

Latest Information Update: 25 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; University of Calgary
  • Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pulmonary hypertension; Heart failure
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Diastolic heart failure; Heart failure; Pulmonary hypertension
  • No development reported Female infertility; Raynaud's disease
  • Discontinued Angina pectoris; Cardiovascular disorders; Eye disorders; Female sexual dysfunction; Meniere's disease

Most Recent Events

  • 25 Nov 2024 Discontinued - Phase-III for Pulmonary hypertension (In neonates) in France (IV) (NDR#31)
  • 30 Sep 2024 Annovis files three new patents for a combination therapy involving Buntanetap, Trulicity, and Viagra
  • 06 Sep 2022 No development reported - Phase-III for Pulmonary hypertension (In neonates) in France (IV) (NDR Batch 23)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top